Study · Non-randomized trial · 1985
6 resultsPiotrowski W, Foreman JC
Naunyn-Schmiedeberg's archives of pharmacology1 Dec 1985Cited by 76 (Europe PMC)
The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)
Text rights: Publisher copyright. Results still quote short attributed sentences.
3 results from studies that gave the peptide. 2 results from people.
In human skin, intradermal injection of VIP produced a flare response.
In plain wordsIn human skin, a VIP injection under the skin produced a flare (skin redness).
n: not reported in source
Source sentences
In human skin, intradermal injection of SP, Som, or VIP produced flare and wheal responses.
In human skin, intradermal injection of VIP produced a wheal response.
In plain wordsIn human skin, a VIP injection under the skin produced a wheal (a raised swelling).
n: not reported in source
Source sentences
In human skin, intradermal injection of SP, Som, or VIP produced flare and wheal responses.
In isolated rat peritoneal mast cells, VIP induced a concentration-dependent release of histamine.
In plain wordsIn lab tests on rat mast cells, VIP caused histamine release that rose with the VIP concentration.
ratn: not reported in source
isolated peritoneal mast cellsSource sentences
Substance P (SP), somatostatin (Som), and vasoactive intestinal polypeptide (VIP) induced a concentration-dependent release of histamine from isolated rat peritoneal mast cells.
In this study, Vasoactive intestinal peptide (VIP, aviptadil) was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Vasoactive intestinal peptide (VIP, aviptadil).
In human skin, preinjection of the substance P analogue SP-A (25 pmol) inhibited the flare responses to VIP and the other peptides.
In plain wordsIn human skin, the substance P blocker SP-A reduced the flare caused by VIP and other peptides.
n: not reported in source
Source sentences
The flares to all three peptides were inhibited by preinjection of the skin with SP-A (25 pmol), whilst the wheal responses were unaffected.
In this study, Vasoactive intestinal peptide (VIP, aviptadil) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Vasoactive intestinal peptide (VIP, aviptadil).
In human skin, preinjection of SP-A did not affect the wheal responses to VIP and the other peptides.
In plain wordsIn human skin, the substance P blocker SP-A did not change the wheal caused by VIP and other peptides.
n: not reported in source
Source sentences
The flares to all three peptides were inhibited by preinjection of the skin with SP-A (25 pmol), whilst the wheal responses were unaffected.
In this study, Vasoactive intestinal peptide (VIP, aviptadil) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Vasoactive intestinal peptide (VIP, aviptadil).
In isolated rat mast cells, preincubation with the substance P analogue SP-A or benzalkonium chloride inhibited histamine release induced by VIP and other neuropeptides.
In plain wordsIn lab tests on rat mast cells, SP-A and benzalkonium chloride reduced histamine release caused by VIP and other neuropeptides.
ratn: not reported in source
isolated peritoneal mast cellsSource sentences
The release of histamine induced by these neuropeptides was inhibited by preincubation of the cells with the SP analogue [D-Pro4,D-Trp7,9,10]-SP4-11 (SP-A) (10 microM), and also by benzalkonium chloride (10 microM).
In this study, Vasoactive intestinal peptide (VIP, aviptadil) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Vasoactive intestinal peptide (VIP, aviptadil).
AI wrote and checked these results. AI can make mistakes, so check important results against the source.
PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.
Version 2Current
12 Oct 2026, 12:58 UTC
Study results updated
Version 1
9 Oct 2026, 12:41 UTC
First added · source update from Europe PMC
Terms as the source lists them.
PepBank is a research reference. Talk to a doctor before you use any peptide.
In PepBank now:147 peptides, 6 blends and 13 other compounds97,577 study results from 17,383 studies8,473 clinical trialsUpdated